| Irfanullah Haider, MD | |
|
3901 Rainbow Blvd, Ms 4032, Kansas City, KS 66160-8500 | |
| (913) 588-5000 | |
| Not Available |
| Full Name | Irfanullah Haider |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 13 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114212024 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 94-08239 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.
New research into the concerns of people with healthcare needs amid COVID-19 were explored, as a panel of industry leaders debated how to transform services to improve UK mental health support, in Connect Health's latest Change webinar.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 7 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.
New research into the concerns of people with healthcare needs amid COVID-19 were explored, as a panel of industry leaders debated how to transform services to improve UK mental health support, in Connect Health's latest Change webinar.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 7 days ago
| Entity Name | West Grove Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790856078 PECOS PAC ID: 4789685033 Enrollment ID: O20070129000812 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.
New research into the concerns of people with healthcare needs amid COVID-19 were explored, as a panel of industry leaders debated how to transform services to improve UK mental health support, in Connect Health's latest Change webinar.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Irfanullah Haider, MD 3901 Rainbow Blvd, Ms 4032, Kansas City, KS 66160-8500 Ph: () - | Irfanullah Haider, MD 3901 Rainbow Blvd, Ms 4032, Kansas City, KS 66160-8500 Ph: (913) 588-5000 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.
New research into the concerns of people with healthcare needs amid COVID-19 were explored, as a panel of industry leaders debated how to transform services to improve UK mental health support, in Connect Health's latest Change webinar.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 7 days ago
Dr. Benjamin Adam Schatz, MD Radiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd # Ms 4032, Kansas City, KS 66160 Phone: 405-416-0500 | |
Pauline R Sleder, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6805 | |
Dr. Steven Mclain Lemons, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd # Ms 4032, Kansas City, KS 66160 Phone: 913-588-6805 | |
Philip L Johnson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Stop 4032, Kansas City, KS 66160 Phone: 913-588-6800 Fax: 913-588-7899 | |
Dr. Ernest John Madarang, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Department Of Radiology, Kansas City, KS 66103 Phone: 913-588-6875 | |
Norman L Martin, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Mail Stop 4032, Kansas City, KS 66160 Phone: 913-588-6800 Fax: 913-588-7899 |